| Lynparza (olaparib) / Merck (MSD), AstraZeneca |
NCT03063710: Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan |
|
|
| No Longer Available | N/A | | Japan | olaparib | AstraZeneca | PSR Ovarian Cancer With a BRCA Mutation | | | | |
| Completed | N/A | 2336 | Europe | olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib | University Hospital, Caen | Cancer | 05/21 | 09/22 | | |
NCT05860530: Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers |
|
|
| Completed | N/A | 48 | RoW | The test olaparib tablet (T), The reference olaparib tablet (R) | Qilu Pharmaceutical Co., Ltd. | Neoplasms | 09/21 | 09/21 | | |
ChiCTR2100051359: Real world study on the efficacy of olaparib in patients with metastatic castration resistant prostate cancer harboring genomic variants in homologous recombination repair genes |
|
|
| Recruiting | N/A | 50 | | Olaparib | Renji Hospital, Shanghai Jiaotong University, School of Medicine; Renji Hospital, Shanghai Jiaotong University, School of Medicine, None | Prostate cancer | | | | |
ROMP, NCT04582552: The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer |
|
|
| Recruiting | N/A | 60 | RoW | PARP inhibitors, Lynparza, Zejula | Xiaoxiang Chen | Ovarian Cancer, Clinical Marker, PARP Inhibitor | 05/22 | 11/23 | | |
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study |
|
|
| Terminated | N/A | 3 | RoW | Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab | Peter MacCallum Cancer Centre, Australia | Cancer | 12/22 | 12/22 | | |
ChiCTR2000036618: Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study |
|
|
| Not yet recruiting | N/A | 18 | | Everolimus 5mg qd + Anlotinib 8mg-12mg day 1-21，28-day cycle ;Camrelizumab 3mg/kg + Ipilimumab 1 mg/kg, 21-days cycle ;Palbociclib 125mg day 1-21 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Olaparib 300mg bid day 1-14 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Metformin 2000mg qd + gemcitabine 675mg/m2 day 1,8, docetaxol 900mg/m2 day 8， 21-days cycle | Shanghai General Hospital; Shanghai General Hospital, Project special fund | osteosarcoma | | | | |
FLAME, NCT05775549: A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer |
|
|
| Completed | N/A | 24 | US | None (Observational Study), Observational Study | AstraZeneca, Merck Sharp & Dohme LLC | Advanced Ovarian Cancer | 10/23 | 10/23 | | |
NCT04699006: Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. |
|
|
| Enrolling by invitation | N/A | 245 | RoW | | First Affiliated Hospital Xi'an Jiaotong University | Ovarian Cancer | 01/24 | 01/26 | | |
PROceed, NCT06380738: Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone |
|
|
| Recruiting | N/A | 250 | Europe | | AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Castration-resistant Prostate Cancer | 01/27 | 01/27 | | |
NCT06324734: Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting |
|
|
| Completed | N/A | 2506 | RoW | | AstraZeneca | Using NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE | 07/24 | 07/24 | | |
PROCeed-BR, NCT06457854: Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone |
|
|
| Not yet recruiting | N/A | 80 | RoW | | AstraZeneca | Prostatic Neoplasms | 09/25 | 09/25 | | |
OVAL-1, NCT04532645: Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK |
|
|
| Active, not recruiting | N/A | 350 | Europe | Olaparib, Lynparza | AstraZeneca | Ovary Cancer | 12/24 | 12/24 | | |
| Recruiting | N/A | 650 | RoW | | AstraZeneca | Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer | 06/25 | 06/25 | | |
DIM-OC, NCT04560452: Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients |
|
|
| Recruiting | N/A | 1000 | RoW | | AstraZeneca | Ovarian Cancer, Prostate Cancer | 12/25 | 12/25 | | |
NCT04889404: LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS) |
|
|
| Active, not recruiting | N/A | 130 | Japan | | AstraZeneca | Pancreatic Neoplasms | 09/25 | 09/25 | | |
NCT05677308: LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS) |
|
|
| Recruiting | N/A | 104 | Japan | | AstraZeneca | Breast Cancer | 12/26 | 12/26 | | |
| Recruiting | N/A | 300 | Europe | | AstraZeneca | Metastatic Castration-resistant Prostate Cancer | 10/28 | 10/28 | | |
